CoChat

New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses

Open access
Kamrani, Amin, Nasiri, Hadi, Hassanzadeh, Ali, Ahmadian Heris, Javad, Mohammadinasab, Reza, Sadeghvand, Shahram, Sadeghi, Mohammadreza, Valedkarimi, Zahra, Hosseinzadeh, Ramin, Shomali, Navid, Akbari, Morteza · 2024 · Cell Communication and Signaling

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Abstract

Colorectal cancer is one of the most common causes of mortality worldwide. There are several potential risk factors responsible for the initiation and progression of colorectal cancer, including age, family history, a history of inflammatory bowel disease, and lifestyle factors such as physical activity and diet. For decades, there has been a vast amount of study on treatment approaches for colorectal cancer, which has led to conventional therapies such as chemotherapy, surgery, etc. Considering the high prevalence and incidence rate, scholars believe there is an urgent need for an alternative, more efficacious treatment with fewer adverse effects than the abovementioned treatments. Immunotherapy has emerged as a potential treatment alternative in a few years and has become one of the fastest-evolving therapeutic methods. Immunotherapy works by activating or enhancing the immune system’s power to identify and attack cancerous cells. This review summarizes the most crucial new immunotherapy methods under investigation for colorectal cancer treatment, including Immune checkpoint inhibitors, CAR-T cell therapy, BiTEs, Tumor-infiltrating lymphocytes, and Oncolytic virus therapy. Furthermore, this study discusses the application of combination therapy, precision medicine, biomarker discovery, overcoming resistance, and immune-related adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12964-023-01430-8

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 New CAR-T cell strategies, such as specific CAR-T cells against PDL-1, CD166/CD318, GB3, and GUCY2C, can be new immunotherapeutic approaches for CRC apoptosis
Fig. 1 New CAR-T cell strategies, such as specific CAR-T cells against PDL-1, CD166/CD318, GB3, and GUCY2C, can be new immunotherapeutic approaches for CRC apoptosisCC BY · PubMed Central
Fig. 2 Bispecific antibodies (BiTE) comprise two flexibly linked single-chain antibodies, one binding to the surface antigen on the target cell and the other to CD3 on T cells. Some new BiTEs against CEA, EGFR, and Cd1d can be immunotherapy strategies
Fig. 2 Bispecific antibodies (BiTE) comprise two flexibly linked single-chain antibodies, one binding to the surface antigen on the target cell and the other to CD3 on T cells. Some new BiTEs against CEA, EGFR, and Cd1d can be immunotherapy strategiesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 83 references

Cited by

See all 50

Metadata

Authors
Kamrani, A., Nasiri, H., Hassanzadeh, A., Ahmadian Heris, J., Mohammadinasab, R., Sadeghvand, S., Sadeghi, M., Valedkarimi, Z., Hosseinzadeh, R., Shomali, N., & Akbari, M.
Affiliations
  • Tabriz University of Medical Sciences (IR)
  • Tehran University of Medical Sciences (IR)
Corresponding author
  • Shomali, Navid
  • Akbari, Morteza
Venue
Cell Communication and Signaling
Published
2024-01-19
Volume
22
Issue
1
Pages
56-56
ISSN
1478-811X (ISSN-L)
OpenAlex
W4391023176
Cited by
50
References
83
Citations by year
2026: 14 · 2025: 20 · 2024: 14
FWCI
2.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Communication and Signaling (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
colorectal cancer, immunotherapy, CAR T-cell therapy, bispecific T-cell engagers, oncolytic virotherapy, immune checkpoint inhibitors, tumor-infiltrating lymphocytes, combination therapy, precision medicine, biomarker discovery, treatment resistance
MeSH terms
Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Colorectal Neoplasms, Immunotherapy, Adoptive, Oncolytic Viruses

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses. https://app.cochat.ai/papers/10.1186/s12964-023-01430-8
The paper
Kamrani, A., Nasiri, H., Hassanzadeh, A., Ahmadian Heris, J., Mohammadinasab, R., Sadeghvand, S., Sadeghi, M., Valedkarimi, Z., Hosseinzadeh, R., Shomali, N., & Akbari, M. (2024). New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses. Cell Communication and Signaling. https://doi.org/10.1186/s12964-023-01430-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.